null

null

null

null

null

null

null

null

null

Minimal debt; pre-revenue clinical-stage biotech funded primarily by equity raises; negligible interest burden, near-zero leverage ratio.

Rising rates increase equity dilution risk and cost of future capital raises; no significant floating-rate debt exposure currently.

Low intensity; China and India supply >60% of global API inputs, creating concentration risk.

1) API synthesis and raw material sourcing from China-based chemical suppliers; 2) CRO/CMO concentration in Eastern Europe and Asia-Pacific.

Minimal international revenue; clinical trials conducted in select markets; negligible sovereign currency devaluation exposure at current stage.

Operations primarily US-based; clinical sites in Europe and Asia; no material revenue in foreign currencies; FX risk is low and non-material.

Low intensity; commodities: Active Pharmaceutical Ingredients, Rare Earth Elements, Natural Gas (energy), Plastics/Resins, Ethanol, Packaging Materials; geopolitical: China and India supply >60% of global API inputs, creating concentration risk.

High dependency on single or limited CROs/CMOs for THIO drug substance manufacturing; substitution would cause significant trial delays.

Clinical-stage biotech; no meaningful cloud infrastructure dependency for core drug development operations; disruption manageable.

Data management and trial operations have minor cloud exposure; secondary disruption risk is low given outsourced IT model.

API coupling risk is low; company relies on standard biotech research software and CRO platforms with moderate switching friction.

Revenue model is grant/equity-funded R&D, not a securities offering; Howey Test not applicable to core operations; low regulatory risk.

Very High

Clinical trial patient data subject to GDPR in European trial sites; CCPA exposure minimal; compliance managed through CRO data agreements.

Negligible antitrust exposure; pre-revenue single-asset biotech with no market dominance or pricing power in any commercial market yet.

Very High burden; regimes: FDA, CMS, HHS, HIPAA, EMA, OIG; Drug pricing legislation and approval delays directly compress revenue visibility.

Effectively 0% recurring commercial revenue; 100% dependent on grants, partnerships, and equity capital raises; no product revenue yet.

Future monetization via licensing deals, partnership milestones, and eventual drug commercialization; currently pre-monetization stage.

No commercial pricing architecture exists; future pricing will be driven by oncology market benchmarks (~$100K–$500K/year treatment cost).

Potential high pricing power if THIO approved in telomere-targeting oncology niche with limited competition; unproven at current stage.

Biopharmaceutical commercialization typically yields 70–90% gross margins; target bracket estimated at 75–85% post-approval.

No current customer base; free-rider leakage not applicable; IP protection via patents is the primary value-retention mechanism.

Lean headcount (~15–25 employees); growth is capital-intensive not headcount-linear; scale achieved via CRO outsourcing model.

Sublinear headcount growth expected; doubling pipeline assets requires more capital but not proportional internal headcount expansion.

Not applicable; MAIA is not a franchise business model.

At 10x scale, CAC would be driven by oncology salesforce buildout; estimated cost per physician relationship $50K–$150K annually.

No meaningful network effects present; biotech drug development does not benefit from user-scale network dynamics.

-230.7% Return on Assets (Negative equity)

Moderate resilience; oncology treatments are non-discretionary, but pre-revenue status makes company highly dependent on capital markets.

Future primary customers: oncologists and cancer treatment centers treating NSCLC and other solid tumor indications.

Secondary customers: large pharma/biotech partners seeking licensing or co-development of telomere-targeting THIO platform.

["11-0000 Management Occupations", "13-0000 Business and Financial Operations Occupations", "15-0000 Computer and Mathematical Occupations", "19-0000 Life, Physical, and Social Science Occupations", "21-0000 Community and Social Service Occupations", "23-0000 Legal Occupations", "29-0000 Healthcare Practitioners and Technical Occupations", "31-0000 Healthcare Support Occupations", "41-0000 Sales and Related Occupations", "43-0000 Office and Administrative Support Occupations", "51-0000 Production Occupations"]

0.32 (HIL — ~32% of characteristic roles agent-automatable)

Capital allocated almost entirely to clinical trials and R&D; no legacy infrastructure; spending directed toward future-state drug approval milestones.

0001878313

MAIA